A Phase 3 interventional study of HTX-011 and Ibuprofen in Analgesia, sponsored by Heron Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Heron Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 87th largest by enrollment, is one of 35 that started in 2019, is one of 42 in phase 3, and was the 186th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 35 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
20 studies in Pain, Postoperative by Heron Therapeutics: none open now, 1 under way, none of them phase 3. Of 18 finished, 16 (89%) have results posted.
Among the 20 studies in Pain, Postoperative by Heron Therapeutics, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 3, and was the 14th registered.
Heron Therapeutics’s Pain, Postoperative studies by the year they started, since 2015.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Heron Therapeutics’s 20 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTX-011 + MMA
Drug: HTX-011 · Drug: Ibuprofen · Drug: Acetaminophen · Drug: Celecoxib · Device: Luer Lock Applicator
HTX-011 + MMA
Drug: HTX-011 · Drug: Ibuprofen · Drug: Acetaminophen · Drug: Celecoxib · Device: Luer Lock Applicator
HTX-011 + MMA
Drug: Ibuprofen · Drug: Acetaminophen · Drug: Celecoxib · Drug: +/- Bupivacaine HCl · Device: Luer Lock Applicator · Drug: HTX-011
HTX-011 + MMA
Drug: HTX-011 · Drug: Ibuprofen · Drug: Acetaminophen · Device: Luer Lock Applicator
Drug pages: Bupivacaine · Meloxicam
Dual-acting local anesthetic. Dose 1.
NSAID.
Analgesic.
NSAID.
Drug page: Bupivacaine
Local anesthetic.
Applicator for instillation.
Drug pages: Bupivacaine · Meloxicam
Dual-acting local anesthetic. Dose 2.
Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).
The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
Time frame: 12 through 48 hours
Mean AUC of VAS Scores.
The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
Time frame: 72 hours
Mean AUC of the NRS of Pain Intensity at Rest (NRS-R).
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain". NRS scores are measured at rest.
Time frame: 72 hours
Percentage of Subjects With Severe Pain.
Severe Pain defined as a VAS score ≥7.5 cm.
Time frame: 24 hours, 48 hours, 72 hours
Mean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]).
Time frame: 72 hours
Percentage of Subjects Who Are Opioid-free
Time frame: 72 Hours to Day 11
Percentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11.
Time frame: 72 hours through Day 11
Median Time to First Opioid Rescue Medication.
Time frame: Through 72 hours
Percentage of Subjects Who do Not Receive an Opioid Prescription at Discharge.
Time frame: 72 hours
Percentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit.
Time frame: 72 hours through Day 11
Percentage of Subjects Achieving a Score of "Good" or Better (>1) Pain Control Based on Patient Global Assessment (PGA).
Patient's Global Assessment (PGA) of pain control is a 4-point scale in which subjects rate how well their pain has been controlled (0 = Poor; 1 = Fair; 2 = Good; 3 = Excellent).
Time frame: 24 hours, 48 hours, 72 hours, Day 11
Median Time to First Ambulation Postsurgery.
Time frame: 72 hours
Percentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain.
Time frame: 72 hours
Percentage of Subjects Who First Achieve an MPADSS Score ≥9.
Subjects were assessed for readiness for discharge using the Modified Post-Anesthesia Discharge Scoring System (MPADSS) that assesses 5 clinical variables: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding, each on a 3-point scale of 0, 1, or 2 with 0 being the worst score and 2 being the best score. Subjects with an MPADSS score of 9 or 10 were considered ready for discharge.
Time frame: 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24, hours, 36 hours, 48 hours, 60 hours, 72 hours
Percentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility.
Number Analyzed represents Subjects who were discharged home.
Time frame: 72 hours
Mean Overall Benefit of Analgesia Score (OBAS).
Subjects were questioned about their overall benefit of analgesia. Overall benefit of analgesia score (OBAS) assesses current pain at rest, vomiting, itching, sweating, freezing, dizziness, and overall satisfaction with postoperative pain during the previous 24 hours. To calculate the OBAS score, each of the subscale scores (0=minimum; 4=maximum) are summed for a combined OBAS score. Possible scores could range from 0 to 28 with a lower score indicating greater benefit.
Time frame: 24 hours, 48 hours, 72 hours, Day 11
Mean Total TSQM-9 Score
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) contains 9 items assessing Effectiveness, Convenience, and Global Satisfaction domains. Responses to items are rated on a 5-point or 7-point rating scale. Scores for each domain are computed by adding the TSQM items in each domain and then transforming the values in to a composite score ranging from 0 to 100, with higher scores representing higher satisfaction.
Time frame: 72 hours through Day 11
Maximum Concentration (Cmax)
Time frame: 72 hours
Time of Occurrence of Maximum Concentration (Tmax)
Time frame: 72 hours
| Milestone | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Started | 66 | 14 | 16 | 20 |
| Completed | 66 | 14 | 16 | 20 |
| Not completed | 0 | 0 | 0 | 0 |
The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
| pain intensity score*hr | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS). | 155.57 ± 95.651 | 185.27 ± 86.898 | 161.36 ± 86.627 | 126.59 ± 118.431 |
The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
| pain intensity score*hr | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Mean AUC of VAS Scores. | 277.03 ± 164.004 | 319.81 ± 158.746 | 276.87 ± 146.578 | 216.18 ± 206.164 |
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain". NRS scores are measured at rest.
| pain intensity score*hr | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Mean AUC of the NRS of Pain Intensity at Rest (NRS-R). | 309.89 ± 155.289 | 355.20 ± 161.377 | 311.00 ± 136.714 | 245.00 ± 200.369 |
Severe Pain defined as a VAS score ≥7.5 cm.
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| 24 Hours | 26 | 4 | 5 | 6 |
| 48 Hours | 29 | 5 | 5 | 6 |
| 72 Hours | 23 | 5 | 5 | 7 |
| MME, morphine milligram equivalency | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Mean Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [MME]). | 26.40 ± 23.229 | 31.50 ± 24.907 | 23.40 ± 14.484 | 17.62 ± 22.167 |
| participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Percentage of Subjects Who Are Opioid-free | 25 | 4 | 3 | 10 |
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Percentage of Subjects Who Are Opioid-free Through 72 Hours Who Remain Opioid-free Through Day 11. | 9 | 1 | 0 | 5 |
| Hours | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Median Time to First Opioid Rescue Medication. | 6.12 (4.27 to 8.25) | 5.63 (2.12 to 19.48) | 9.96 (4.18 to 15.90) | 12.76 (5.80 to 47.10) |
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Percentage of Subjects Who do Not Receive an Opioid Prescription at Discharge. | 41 | 8 | 12 | 13 |
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Percentage of Subjects Who do Not Receive an Opioid Prescription Between Discharge and the Day 11 Visit. | 44 | 8 | 8 | 17 |
Patient's Global Assessment (PGA) of pain control is a 4-point scale in which subjects rate how well their pain has been controlled (0 = Poor; 1 = Fair; 2 = Good; 3 = Excellent).
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| 24 Hours | 60 | 10 | 14 | 16 |
| 48 Hours | 61 | 11 | 14 | 16 |
| 72 Hours | 66 | 12 | 15 | 18 |
| Day 11 | 50 | 11 | 11 | 15 |
| Hours | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Median Time to First Ambulation Postsurgery. | 20.66 (18.48 to 23.43) | 23.20 (6.08 to 54.62) | 26.72 (24.37 to 29.60) | 20.58 (5.83 to 23.92) |
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Percentage of Subjects Unable to Participate in Each Rehabilitation Session Because of Pain. | 23 | 1 | 2 | 3 |
Subjects were assessed for readiness for discharge using the Modified Post-Anesthesia Discharge Scoring System (MPADSS) that assesses 5 clinical variables: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding, each on a 3-point scale of 0, 1, or 2 with 0 being the worst score and 2 being the best score. Subjects with an MPADSS score of 9 or 10 were considered ready for discharge.
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Through 2 Hours | 15 | 2 | 2 | 0 |
| Through 4 Hours | 16 | 3 | 2 | 3 |
| Through 6 Hours | 21 | 6 | 5 | 7 |
| Through 8 Hours | 29 | 6 | 8 | 8 |
| Through 12 Hours | 38 | 7 | 9 | 8 |
| Through 24 Hours | 45 | 8 | 11 | 15 |
| Through 36 Hours | 52 | 12 | 13 | 18 |
| Through 48 Hours | 57 | 12 | 13 | 19 |
| Through 60 Hours | 57 | 12 | 15 | 19 |
| Through 72 Hours | 59 | 13 | 15 | 19 |
Number Analyzed represents Subjects who were discharged home.
| Participants | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Percentage of Subjects Who Are Discharged Home vs to a Skilled Nursing Facility. | 61 | 10 | 16 | 20 |
Subjects were questioned about their overall benefit of analgesia. Overall benefit of analgesia score (OBAS) assesses current pain at rest, vomiting, itching, sweating, freezing, dizziness, and overall satisfaction with postoperative pain during the previous 24 hours. To calculate the OBAS score, each of the subscale scores (0=minimum; 4=maximum) are summed for a combined OBAS score. Possible scores could range from 0 to 28 with a lower score indicating greater benefit.
| Scores on a scale | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| 24 Hours | 6.5 ± 2.75 | 7.4 ± 6.36 | 7.6 ± 3.24 | 5.9 ± 3.45 |
| 48 Hours | 5.7 ± 2.76 | 4.9 ± 1.44 | 5.9 ± 2.89 | 5.3 ± 2.57 |
| 72 Hours | 5.1 ± 2.46 | 4.1 ± 1.77 | 4.9 ± 1.88 | 4.8 ± 2.29 |
| Day 11 | 5.0 ± 2.43 | 5.2 ± 2.08 | 4.9 ± 2.08 | 4.9 ± 2.07 |
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) contains 9 items assessing Effectiveness, Convenience, and Global Satisfaction domains. Responses to items are rated on a 5-point or 7-point rating scale. Scores for each domain are computed by adding the TSQM items in each domain and then transforming the values in to a composite score ranging from 0 to 100, with higher scores representing higher satisfaction.
| Scores on a scale | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Global Satisfaction Domain - 72 Hours | 86.9 ± 15.53 | 77.0 ± 22.62 | 89.3 ± 14.75 | 86.8 ± 13.57 |
| Effectiveness Doman - 72 Hours | 86.4 ± 18.09 | 80.2 ± 20.52 | 84.0 ± 14.61 | 81.9 ± 15.39 |
| Convenience Domain - 72 Hours | 90.1 ± 12.03 | 84.5 ± 17.18 | 93.1 ± 13.07 | 86.9 ± 16.45 |
| Global Satisfaction Domain - Day 11 | 78.0 ± 22.39 | 74.5 ± 27.27 | 72.8 ± 21.22 | 82.9 ± 18.16 |
| Effectiveness Doman - Day 11 | 76.3 ± 21.18 | 69.4 ± 29.13 | 69.4 ± 29.13 | 67.0 ± 24.80 |
| Convenience Domain - Day 11 | 90.1 ± 12.03 | 86.9 ± 15.50 | 80.9 ± 15.31 | 90.6 ± 12.24 |
| ng/mL | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Bupivacaine | 566 ± 273 | 534 ± 175 | 742 ± 268 | 851 ± 288 |
| Meloxicam | 238 ± 96.8 | 247 ± 89.0 | 251 ± 104 | 385 ± 161 |
| hours | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| Bupivacaine | 21.05 (1.07 to 49.83) | 20.54 (3.98 to 37.27) | 20.14 (2.10 to 37.02) | 22.48 (8.05 to 48.63) |
| Meloxicam | 47.13 (18.38 to 49.83) | 58.58 (23.65 to 73.28) | 37.17 (20.35 to 71.43) | 48.58 (20.85 to 73.37) |
Collected over From the time the subject signed the informed consent form (ICF) through the Day 29 Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 and Cohort 2 (Pooled) | 0/66 (0%) | 2/66 (3%) | 56/66 (84.8%) |
| Cohort 3: Group A | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| Cohort 3: Group B | 0/16 (0%) | 0/16 (0%) | 14/16 (87.5%) |
| Cohort 4 | 0/20 (0%) | 2/20 (10%) | 15/20 (75%) |
| Event | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| TachycardiaCardiac disorders | 0/66 | 0/14 | 0/16 | 1/20 |
| HypertensionVascular disorders | 0/66 | 0/14 | 0/16 | 1/20 |
| GastritisGastrointestinal disorders | 1/66 | 0/14 | 0/16 | 0/20 |
| Post procedural haematomaInjury, poisoning and procedural complications | 1/66 | 0/14 | 0/16 | 0/20 |
| Event | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 33/66 | 6/14 | 11/16 | 6/20 |
| VomitingGastrointestinal disorders | 17/66 | 3/14 | 7/16 | 5/20 |
| ConstipationGastrointestinal disorders | 10/66 | 3/14 | 6/16 | 2/20 |
| BradycardiaCardiac disorders | 3/66 | 3/14 | 2/16 | 0/20 |
| Urinary retentionRenal and urinary disorders | 3/66 | 3/14 | 0/16 | 0/20 |
| Oedema peripheralGeneral disorders | 1/66 | 3/14 | 1/16 | 0/20 |
| Procedural painInjury, poisoning and procedural complications | 1/66 | 1/14 | 3/16 | 0/20 |
| Incision site erythemaInjury, poisoning and procedural complications | 0/66 | 2/14 | 0/16 | 0/20 |
| DizzinessNervous system disorders | 9/66 | 1/14 | 2/16 | 1/20 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 9/66 | 0/14 | 0/16 | 0/20 |
| Age, Categorical(Participants) | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 6 | 6 | 7 | 54 |
| >=65 years | 31 | 8 | 10 | 13 | 62 |
| Age, Continuous(years) | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 | Total |
|---|---|---|---|---|---|
| Mean | 64.0 ± 9.64 | 62.4 ± 8.88 | 66.8 ± 9.81 | 69.0 ± 8.82 | 65.1 ± 9.64 |
| Sex: Female, Male(Participants) | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 37 | 4 | 12 | 12 | 65 |
| Male | 29 | 10 | 4 | 8 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 20 | 1 | 3 | 5 | 29 |
| Not Hispanic or Latino | 46 | 13 | 13 | 15 | 87 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 3 | 5 | 17 |
| White | 59 | 11 | 13 | 15 | 98 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Cohort 1 and Cohort 2 (Pooled) | Cohort 3: Group A | Cohort 3: Group B | Cohort 4 | Total |
|---|---|---|---|---|---|
| United States | 66 | 14 | 16 | 20 | 116 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Dec 2020, 18 months.
Results were first posted in Aug 2023, 2 years 8 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 18 months is above that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Meloxicam